title: Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
abstract: OBJECTIVE
  To assess the effect of a supratherapeutic dose of the integrase inhibitor dolutegravir on the QT and corrected QT (QTc) interval.
  
  
  METHODS
  Randomized, partial-blind, placebo-controlled, single-dose, 3-period, balanced crossover study.
  
  
  METHODS
  Clinical research unit.
  
  
  METHODS
  Forty-two healthy subjects were randomized; of these subjects, 38 completed the study, three withdrew early because of protocol violations, and one was lost to follow-up.
  
  
  METHODS
  Subjects were randomized to receive three single doses of the following treatments: dolutegravir 250-mg suspension, moxifloxacin 400-mg tablet, and placebo suspension; each treatment was separated by a 14-day washout period. Treatment with the dolutegravir and placebo suspension was blinded, whereas treatment with moxifloxacin was open label.
  
  
  RESULTS
  The pharmacokinetic exposure at a supratherapeutic dose of dolutegravir 250 mg was 2-4 times higher than the pharmacokinetic exposure at clinically relevant dosages (50 mg once or twice/day). The upper limit of the 90% confidence interval (CI) for the placebo-adjusted mean change from baseline of the QTc interval (ΔΔQTcF) using Fridericia's formula was less than 10 msec at all time points. The sensitivity of the study to detect modest increases in QT interval was established with moxifloxacin, a positive control for QT-interval prolongation. The maximum ΔΔQTcF values for dolutegravir and moxifloxacin were observed at 4 hours: 1.99 msec (90% CI -0.55-4.53 msec) and 9.58 msec (90% CI 7.05-12.11 msec), respectively.
  
  
  CONCLUSIONS
  This pharmacokinetic-pharmacodynamic model demonstrates no relationship between dolutegravir plasma concentration and ΔΔQTcF. Furthermore, a supratherapeutic dose of dolutegravir was generally well tolerated without any serious or severe adverse events. As such, dolutegravir does not affect cardiac repolarization.
authors.affiliation: Infectious Diseases Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA.
authors.forename: Shuguang
authors.initials: S
authors.lastname: Chen
authors.forename: Sherene S
authors.initials: SS
authors.lastname: Min
authors.forename: Amanda
authors.initials: A
authors.lastname: Peppercorn
authors.forename: Julie
authors.initials: J
authors.lastname: Borland
authors.forename: Yu
authors.initials: Y
authors.lastname: Lou
authors.forename: Ivy
authors.initials: I
authors.lastname: Song
authors.forename: Tamio
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Piscitelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D001372:Aza Compounds / Q000009:adverse effects; D016001:Confidence Intervals; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006329:Heart Conduction System; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D011804:Quinolines / Q000009:adverse effects; D012959:Socioeconomic Factors; D055815:Young Adult; D000099226:Dolutegravir
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D000077266:Moxifloxacin; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D011804:Quinolines; D000099226:Dolutegravir